



**Supplementary Data:** Hemani R et al, Dietary pterostilbene for MTA1-targeted interception in high-risk premalignant prostate cancer



**Figure S1.** A, transgene integration and genotyping scheme of MTA1 transgenic animals. Upper panel: genomic sequence at R26 landing pad; lower panel: female founder with MTA1 transgene inserted at 1,3-attP sites. B, genotyping of MTA1 founder 870#2. *Left:* 425N/436N (lane 1); 425N/CAG-R (lane 2); MTA1-F/eGFP-R3 (lane 3); polyA-Fu/Frt-R2 (lane 4); 522N/Frt-R2 (lane 5); *right,* 100bp ladder DNA marker used in lanes M. Applied StemCell, Inc. [www.appliedstemcell.com](http://www.appliedstemcell.com)



**Figure S2.** A, average body weight of mice fed different diets during 22 weeks (monitored weekly). B, effect of PTER-Diet on food intake (g). Values are mean  $\pm$  SEM, n=20 (*R26<sup>MTA1</sup>; Pten<sup>+/-</sup>*) and n=10 (*Pten<sup>+/-</sup>*) mice per group.

**Table S1.** Nutritional composition of diets

Nutrient	Ctrl-Diet		PTER-Diet	
	% weight (g)	% kcal from	% weight (g)	% kcal from
Protein	17.7	21.5	17.7	18.8
Carbohydrates	64.9	63.0	64.9	68.8
Fats	5.2	15.5	5.2	12.4
Total (kcal/g)	3.2		3.8	

Adapted and edited from: <https://www.envigo.com/p/teklad/> Ctrl, control; PTER, pterostilbene

**Table S2.** Primers for genotyping used in this study.

<b>Primers</b>	<b>Sequence</b>
MTA1 forward	5'- GCT GCT CTC ATC CTC AGA AAC C - 3'
MTA1 reverse	5'- CTC GAT GTT GTG GCG GAT CTT GAA GTT - 3'
Pten forward	5'- CAA GCA CTC TGC GAA CTG AG -3'
Pten reverse	5'- AAG TTT TTG AAG GCA AGA TGC -3'
Cre forward	5'- TCG CGA TTA TCT TCT ATA TCT TCA G - 3'
Cre reverse	5'- GCT CGA CCA GTT TAG TTA CCC -3'
Luc forward	5'- GCC ATT CTA TCC GCT GGA AG - 3'
Luc reverse	5'- GCT GCG AAA TGC CCA TAC TG - 3'
Rosa26 forward	5'- AGT TCT CTG CTG CCT CCT GGC TTC T - 3'
Rosa26 reverse	5'- CAT AAA CCC CAG ATG ACT CCT ATC CTC - 3'

**Table S3.** Antibodies for immunoblots and IHC used in this study.

<b>Antibody</b>	<b>Method</b>	<b>Dilution</b>	<b>Source</b>	<b>Catalog#</b>
MTA1	Immunoblot IHC	1: 2500 1 : 50	Cell Signaling Technologies	5647
Cyclin D1	Immunoblot	1:1000	Cell Signaling Technologies	2922S
Notch2	Immunoblot	1:1000	Cell Signaling Technologies	57325
Akt	Immunoblot	1:1000	Cell signaling Technology	4691
pAkt	Immunoblot	1:1000	Cell Signaling Technology	4060
IL-1 $\beta$	Immunoblot	1:200	Santa Cruz Biotechnology	sc-32294
PCNA	Immunoblot	1:1000	Cell Signaling Technology	2586
p27	Immunoblot	1:100	Santa Cruz Biotechnology	sc-1641
NF- $\kappa$ B	Immunoblot	1:200	Santa Cruz Biotechnology	sc-7151
E-cad	Immunoblot	1:1000	Cell Signaling Technology	3195
HSP70	Immunoblot	1:2500	Santa Cruz Biotechnology	sc-24
$\beta$ -actin	Immunoblot	1:2500	Santa Cruz Biotechnology	sc-69879

GFP	Immunoblot	1:500	Santa Cruz Biotechnology	sc-9996
Ki67	IHC	1: 50	Abcam	Ab16667
SMA	IHC	1:800	Abcam	Ab5694
CD31	IHC	1:500	Cell Signaling Technology	77699

**Table S4.** Primers for qRT-PCR used in this study.

<b>Primers (mRNA)</b>	<b>Sequence</b>
MTA1 forward	5'- AGC TAC GAG CAG CAC AAC GGG GT - 3'
MTA1 reverse	5'- CAC GCT TGG TTT CCG AGG AT - 3'
Cyclin D1 forward	5'- GAT CAA GTG TGA CCC GGA CT -3'
Cyclin D1 reverse	5'- TCC TCC TCT TCC TCC TCC TC -3'
Notch2 forward	5'- TGT GAC ATA GCA GCC TCC AG- 3'
Notch2 reverse	5'- AGG GGG CAC TGA CAG TAA T -3'
$\beta$ -actin forward	5'- CGT GGG CCG CCC TAG GCA CCA - 3'
$\beta$ -actin reverse	5'- TTG GCT TAG GGT TCA GGG GGG - 3'